A number of other equities analysts have also commented on the company. SunTrust Banks lowered Medidata Solutions from a “buy” rating to a “hold” rating and set a $79.00 price objective on the stock. in a research note on Wednesday, April 24th. William Blair initiated coverage on Medidata Solutions in a research note on Monday, April 15th. They issued an “outperform” rating and a $74.93 price objective on the stock. TheStreet raised Medidata Solutions from a “c+” rating to a “b-” rating in a research note on Friday, March 15th. Piper Jaffray Companies lifted their price objective on Medidata Solutions from $83.00 to $96.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 30th. Finally, Dougherty & Co lowered Medidata Solutions from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Medidata Solutions presently has an average rating of “Hold” and an average price target of $85.26.
Shares of Medidata Solutions stock traded up $0.08 during midday trading on Thursday, reaching $91.45. The company had a trading volume of 5,605,925 shares, compared to its average volume of 831,825. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.57 and a quick ratio of 2.57. The firm has a market cap of $5.90 billion, a P/E ratio of 95.26, a P/E/G ratio of 8.59 and a beta of 1.32. Medidata Solutions has a fifty-two week low of $60.10 and a fifty-two week high of $98.60.
Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.45 EPS for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.33. The company had revenue of $173.50 million for the quarter, compared to analyst estimates of $172.12 million. Medidata Solutions had a return on equity of 9.28% and a net margin of 7.99%. The firm’s quarterly revenue was up 16.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.40 earnings per share. Equities analysts anticipate that Medidata Solutions will post 0.79 earnings per share for the current fiscal year.
In related news, Director Robert Taylor sold 3,294 shares of the company’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $90.88, for a total transaction of $299,358.72. Following the completion of the sale, the director now owns 41,757 shares in the company, valued at $3,794,876.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.70% of the company’s stock.
Large investors have recently made changes to their positions in the business. Quadrant Capital Group LLC grew its stake in Medidata Solutions by 126.8% in the 1st quarter. Quadrant Capital Group LLC now owns 592 shares of the company’s stock valued at $40,000 after purchasing an additional 331 shares during the period. Bronfman E.L. Rothschild L.P. lifted its position in shares of Medidata Solutions by 26.9% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,286 shares of the company’s stock valued at $87,000 after buying an additional 273 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Medidata Solutions during the 4th quarter valued at $90,000. Canton Hathaway LLC purchased a new position in shares of Medidata Solutions during the 1st quarter valued at $109,000. Finally, Advisor Group Inc. lifted its position in shares of Medidata Solutions by 27.1% during the 4th quarter. Advisor Group Inc. now owns 2,553 shares of the company’s stock valued at $173,000 after buying an additional 545 shares during the last quarter.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Featured Article: What is channel trading?
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.